RESEARCH

Screening for mutations in selected miRNA genes in hypogonadotropic hypogonadism patients

Anna-Pauliina Iivonen1, Johanna Känsäkoski1, Kirsi Vaaralahti1 and Taneli Raivio1,2

1Institute of Biomedicine/Physiology, Biomedicum Helsinki and Stem Cells and Metabolism Research Program, University of Helsinki, Helsinki, Finland
2New Children’s Hospital, Pediatric Research Center, Helsinki University Hospital, Helsinki, Finland

Correspondence should be addressed to T Raivio: taneli.raivio@helsinki.fi

Abstract

In approximately half of congenital hypogonadotropic hypogonadism (cHH) patients, the genetic cause remains unidentified. Since the lack of certain miRNAs in animal models has led to cHH, we sequenced human miRNAs predicted to regulate cHH-related genes (MIR7-3, MIR141, MIR429 and MIR200A-C) in 24 cHH patients with Sanger sequencing. A heterozygous variant in MIR200A (rs202051309; general population frequency of 0.02) was found in one patient. Our results suggest that mutations in the studied miRNAs are unlikely causes of cHH. However, the complex interplay between miRNAs and their target genes in these diseases requires further investigations.

Key Words
- microRNA
- mutation
- hypogonadotropic hypogonadism
- Kallmann syndrome

Introduction

Congenital hypogonadotropic hypogonadism (cHH) is a rare genetic disease that prevents pubertal development and causes infertility due to deficient secretion or action of gonadotropin-releasing hormone (GnRH) (1). Congenital hypogonadotropic hypogonadism is called normosmic (ncHH) if patients have normal sense of smell, whereas Kallmann syndrome (KS) is a form of the same disease where patients have absent or deficient smell (2). In the case of normosmic cHH, abnormal GnRH function results from mutations affecting GnRH signaling, whereas in the case of KS, development of the olfactory system along with the development and/or migration of the GnRH neurons are disrupted (1, 3). These diseases have great phenotypic and genetic heterogeneity, as to date over 30 genes underlying ncHH and KS have been identified (1). Several ncHH and KS disease genes are yet to be discovered, since currently known genes account for only half of all cases (1).

miRNAs are small (~22 nt long) non-coding RNAs that suppress gene expression by binding with 3′UTRs of their target mRNAs. Binding of a miRNA with its target mRNA induces the mRNA’s translational repression or decay (4). miRNAs from individual gene families typically target hundreds of miRNAs, and over 60% of human protein-coding genes are miRNA targets (5). The significance of miRNAs in the hypothalamus–pituitary–gonadal system regulation has been shown in several animal models. Garaffo et al. showed that miR-200 (named miR-8 in miRBase) and miR-9 gene families are required for early GnRH neuron genesis and migration and that lack of these miRNAs lead to KS phenotypes in zebrafish (6, 7). In turn, Ahmed et al. demonstrated that homozygous knockout mice lacking miR7a-2, a miR-7 family member and precursor, recapitulated the phenotype of normosmic cHH (8). Therefore, we asked if some miRNA genes (or their closest human equivalents), which are known to regulate the hypothalamus–pituitary–gonadal system in animals, could be mutated in ncHH or KS patients without genetic diagnoses. Members of the miR-200 (miR-8) gene family, MIR141, MIR429 and MIR200A-C, were selected for screening based on previous evidence (6, 7) and...
MIR7-3 based on literature (9) and bioinformatic analyses by using miRWalk 3.0 (10, 11) and BLAT (12) and BLASTN (13) tools in Ensembl (14).

Subjects and methods

We studied a set of 19 KS and 5 normosmic cHH patients without previously found mutations in known cHH-causing genes (26, 27). Informed consent was obtained from all patients, and in the case of minor/children, a parent or guardian gave the consent. The study was approved by the Ethics Committee of the Hospital District of Helsinki and Uusimaa, and it was conducted in accordance with the Declaration of Helsinki.

The RNA-coding exons and exon-untranslated region boundaries of MIR141 (ENSG00000207708, ENST00000384975.1), MIR429 (ENSG00000198976, ENST000003262106.1), MIR200A (ENSG00000207607, ENST00000384875.3), MIR200B (ENSG00000207730, ENST00000384997.3) and MIR200C (ENSG00000207713, ENST00000384980.3) were amplified by means of PCR from the genomic DNA of the Kallmann patients and the equivalent regions of MIR7-3 (ENSG00000207630, ENST00000384898.1) from the genomic DNA of the ncHH patients. The PCR conditions and primers are available upon request. The PCR products were purified with ExoProStar treatment (GE Healthcare Life Sciences) and sequenced from both directions with the ABI BigDye Terminator Cycle Sequencing Kit (v3.1) and ABI Prism 3730xl DNA Analyzer automated sequencer (Applied Biosystems). The DNA sequences were aligned and read with Sequencher 4.9 software (Gene Codes Corporation, AnnArbor, MI, USA). Allele frequency of the identified variant was validated from the Genome Aggregation Database (gnomAD) (http://gnomad.broadinstitute.org/) (28). gnomAD contains WGS and exome data of 141,456 individuals including 12,562 Finnish samples.

The mouse gene Mir7-2 was aligned against the human reference genome (GRCh38) with the BLAT (12) and BLASTN (13) tools in Ensembl database (14). The BLAT search was run with ‘Genomic sequence’ and the BLASTN search with ‘Ensembl Non-coding RNA genes’ as DNA databases. In both alignment types, other settings were default and the mouse reference genome (CL57BL6) was applied as a control genome. BLAT found hits in two genes, MIR7-3 and MIR7-3HG, with score 46 (probability 3.6e-05). BLASTN found hits in several genes, among which MIR3529 and MIR7-2 had the highest score (52, probability 5e-07) and MIR7-3 and MIR7-1 the second-highest score (48.1, probability 9e-06).

miRWalk 3.0 (http://mirwalk.umm.uni-heidelberg.de/) search with default settings was applied to find the predicted target genes of hsa-miR-7-5p (7).

Results

To find out if mutations in miRNA genes, which are predicted to regulate the hypothalamus–pituitary–gonadal system, could underlie KS/ncHH, our 19 KS patients were screened for mutations in MIR141, MIR429 and MIR200A-C, and 5 ncHH patients for mutations in MIR7-3. We amplified and Sanger-sequenced the coding exons and exon–intron boundaries of the selected genes from the patient genomic DNA. A heterozygous variant, c.42C>T, rs202051309, with a frequency of 0.01996 in the Finnish population in gnomAD, was found in MIR200A in one KS patient. There were no mutations in other investigated miRNA genes.

Discussion

Mutations in miRNA genes may alter the target specificity and processing of miRNAs and cause disease (4, 15). For example, a mutation in the MIR96 gene has been shown to alter the miR-96 biogenesis and, consequently, cause autosomal dominant deafness in an Italian family (16). A SNP in MIR140 is known to alter the miR-140 precursor processing and be associated with familial isolated cleft palate (17), whereas a mutation in MIR184 underlies familial severe keratoconus combined with early-onset cataract (18). To the best our knowledge, however, miRNA genes have not been investigated in patients with chH to date.

Members of the miR-200 (miR-8) family are expressed in the mouse and zebrafish olfactory tissues (19, 20) and are required for the olfactory progenitor cell differentiation in mice (20). Moreover, miR-200 miRNAs are expressed in the GnRH neurons and pituitary, and they play a role in reproduction and fertility in mice (21, 22). Lack of miR-200 members recapitulated KS phenotypes in zebrafish (6). As previous studies strongly indicate their role in the olfactory system and GnRH neuron development, genes of the miR-200 (miR-8) family, MIR141, MIR429, MIR200A, MIR200B and MIR200C, were chosen for screening in our KS patients. In the current study, we identified one variant (c.42C>T, rs202051309) in MIR200A in one of our KS patients. As its general population frequency was relatively high (0.01996), we concluded that it is unlikely to cause disease. However, our patient cohort was limited in size and we cannot fully exclude the possible effect of
this variant on target specificity or miRNA processing. Indeed, if one assumes that mutations in the mir-200 family genes selected for the current study caused 10% of KS, we would have had an 86% chance to detect at least one such a mutation among our 19 KS patients.

Based on the results by Ahmed et al. (8), literature (9) and our bioinformatic analyses, we chose MIR7-3 for screening of our normosmic cHH patients. In brief, all human miR-7-encoding genes (MIR7-1, MIR7-2 and MIR7-3) produce primary miRNAs that are subsequently processed into pre-miRNAs and finally into the same mature miR-7 (4, 9). Most of the miR-7 expression in the human pituitary is presumably attributed to MIR7-3 that is located in an intron of the pituitary-specific gene PGSF1 (pituitary gland specific factor 1, also known as MIR7-3HG, MIR7-3 host gene) (23, 24, 25). In addition, the predicted target genes of the mature human miR-7, hsa-miR-7-5p, include several of the murine miR-7 predicted target genes, such as Glg1, Ptgfrn, Sema4c and Chd3 (8) and currently known nHH/KS genes such as GNRRH, FGFRI, SEMA7A and PROK2 (see Subjects and methods; (1)). However, we found no mutations in MIR7-3, which implies it might rarely be mutated in nCHH, suggesting that the miRNA it encodes has no implications in the human cHH.

In conclusion, this study is the first on miRNAs in cHH. Based on our results, mutations in the examined miRNAs seem to be a rare cause of cHH. We acknowledge that our approach is limited, as we selected specific RNA genes with implicated significance in animal experiments. An unbiased human tissue RNA expression analysis might imply that the most central human and animal miRNAs differ in the hypothalamus–pituitary–gonadal axis. Thus, we cannot exclude the possibility that the examined, or other miRNAs, might contribute to the development and function of the hypothalamus–pituitary–gonadal axis in humans.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by the Academy of Finland, Foundation for Pediatric Research, Sigrid Juselius Foundation, Novo Nordisk Foundation, Emil Aaltonen Foundation, University of Helsinki, Helsinki University Central Hospital and Paiviikki and Sakari Sohlberg Foundation.

Author contribution statement
T R conceived and designed the research, A I and J K performed the experiments and all authors participated in analyzing the results and writing the manuscript.

References


22 Hasuwa H, Ueda J, Ikawa M & Okabe M. miR-200b and miR-429 function in mouse ovulation and are essential for female fertility. *Science* 2013 **341** 71–73. (https://doi.org/10.1126/science.1237999)


26 Laitinen E, Tommiska J, Sane T, Vaaralahti K, Toppari J & Raivio T. Reversible congenital hypogonadotrophic hypogonadism in patients with CHD7, FGFR1 or GNRHR mutations. *PLoS ONE* 2012 **7** e39450. (https://doi.org/10.1371/journal.pone.0039450)


Received in final form 27 March 2019
Accepted 29 March 2019